News
Hadassah Cancer Research Institute (HCRI) Announces Groundbreaking Advance in Personalized Cancer Care
Hadassah Cancer Research Institute (HCRI), a leading force in advancing cancer treatments, unveils a significant breakthrough in personalized cancer care. This research, published
Combining neoadjuvant radiotherapy with SBRT followed by IOeRT boost at surgery appears feasible and safe. This strategy demonstrated high local control and low toxicity following the resection of pancreatic cancer. However, longer follow-up and larger-scale studies are necessary.
G. Cornejo, A. Pikarsky, P. Blumenfeld, M. Wygoda, J. Feldman, A. Hubert,L. Appelbaum-Pikarsky, A. Khalaila,A. Imam, G. Zamir Introduction � The prognosis following
Stereotactic Body Radiotherapy compared to Conventionally Fractionated Radiotherapy for Locally Advanced or Oligometastatic Pancreatic Cancer
�Ofri Mizrahi*, Tal FalickMichaeli*, Ayala Hubert, Marc Wygoda, Philip Blumenfeld Hadassah Medical Center, Department of Radiation Oncology, SharettOncology Center� BACKGROUND � Pancreatic cancer,
Groundbreaking, rapid cancer screening test developed at HCRI achieves 78% accuracy.
HCRI medical researchers led by Dr. Iris Lavon – Head of the Molecular Neuro-Oncology lab at Sharett Oncology Institute and Dr. Aviad Zick
Pioneering Paths in Oncology: CanceRNA Hosts Its 2nd Annual Meeting Focusing on RNA-Based Cancer Therapies at CRG, Barcelona
Barcelona, Spain � The luminous city of Barcelona became a beacon of hope and innovation in the realm of oncology as CanceRNA, an
CanceRNA: Harnessing the Power of RNA Processing for Anti-Cancer Immunotherapy � A Successful First Annual Meeting
On June 29, 2022, CanceRNA marked a significant milestone with its first annual meeting. This virtual assembly provided a vital opportunity for our
